Abstract：Objective: To investigate the effect of ticagrelor on the plasma lipoprotein-related phospholipase A2 (Lp-PLA2) and cardiac function in patients with unstable angina pectoris of coronary heart disease. Methods: A total of 80 patients admitted to our hospital from July 2018 to May 2020 were selected and randomly divided into control group and study group with 40 cases in each by the random number table method. The control group received conventional treatment, and the study group was taking ticagrelor antiplatelet therapy on the basis of control group. The plasma Lp-PLA2, platelet indexes and cardiac function indexes were tested and compared and analyzed after the treatment. Results: After treatment, the maximum platelet aggregation rate of Lp-PLA2 in the study group was significantly lower than that of the control group (P<0.05), and the effective platelet inhibition rate was significantly higher than that of the control group (P<0.05); compared with the control group, SV, FS, EF and other cardiac function indexes of the study group after treatment were significantly higher, and LVDd was significantly lower (P<0.05); the clinical treatment effect of angina pectoris in the study group was significantly better than that of the control group. The results of multivariate logistic regression analysis showed that LpPLA2 was an independent risk factor for the efficacy of angina pectoris, and SV was a protective factor for the efficacy of angina pectoris. Conclusion: Ticagrelor can effectively inhibit platelet aggregation in patients with unstable angina pectoris of coronary heart disease, enhance the antiplatelet coagulation effect, effectively improve the heart function of patients, and the therapeutic effect is more significant. The therapeutic effect of angina pectoris is related to multiple factors such as Lp-PLA2 and SV.
2021, Vol. 27 
冀公网安备13080202000677号